Literature DB >> 18778357

Can autologous myoblasts be used as a potential bulking agent?

Michael Mitterberger1, Rainer Marksteiner, Wolfgang Schwaiger, Günther Klima, Christian Schwentner, Tilko Müller, Georg Bartsch, Christian Radmayr, Hannes Strasser, Josef Oswald.   

Abstract

OBJECTIVE: To investigate the behaviour of donor myoblasts at the vesico-ureteric junction (VUJ) and to evaluate their potential as an autologous bulking agent, as myoblast transplantation has been shown to regenerate damaged or degenerated tissue, and it was postulated that they could be used to treat vesico-ureteric reflux.
MATERIALS AND METHODS: Muscle biopsies were obtained from the lower limb muscles of 10 pigs. The quality of the cells was evaluated by electrophysiological and immunohistochemical tests. The cell membranes of myoblasts were labelled with PKH26, a fluorescent dye. Six weeks after taking of the muscle biopsies all pigs underwent cell transplantation; 30 x 10(6) cells suspended in transplantation medium (in 1-mL syringes) were injected at the VUJ, into the proximal urethra and the rhabdosphincter. At the VUJ volumes of 1 mL were injected, whereas in the urethra and rhabdosphincter small cell depots (0.1 mL) were injected. All the pigs were killed 8 weeks later, and the myoblasts and newly formed myofibres were identified using fluorescence microscopy, with a histological evaluation and investigation of potential local inflammatory reaction.
RESULTS: Two to three intact layers of autologous myoblasts were found in the outer aspects of the large cell depots in the VUJ. Immunohistochemistry further showed that the myoblasts were only viable at these outermost borders of the large bulking areas, whereas necrosis with red fluorescent cell detritus was visible in the remaining central aspects of the large bulk of cells. By contrast, cells survived and formed myotubes in the wall of the proximal urethra and the rhabdosphincter where the small cell depots had been injected.
CONCLUSIONS: In small depots, transplanted autologous myoblasts can survive and differentiate into myofibres, while in a large bulk of cells the vast majority of cells become necrotic. The present results show that myoblasts cannot be used for augmentation of large volumes of tissue or as a bulking agent.

Entities:  

Mesh:

Year:  2008        PMID: 18778357     DOI: 10.1111/j.1464-410X.2008.07892.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

Review 1.  Vesicoureteral reflux: From prophylaxis to surgery.

Authors:  Anne-Sophie Blais; Stéphane Bolduc; Katherine Moore
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

Review 2.  The bladder extracellular matrix. Part II: regenerative applications.

Authors:  Karen J Aitken; Darius J Bägli
Journal:  Nat Rev Urol       Date:  2009-11       Impact factor: 14.432

3.  Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells.

Authors:  Levilester Salcedo; Marc Penn; Margot Damaser; Brian Balog; Massarat Zutshi
Journal:  Stem Cells Transl Med       Date:  2014-05-05       Impact factor: 6.940

Review 4.  Urethral bulking agents: techniques and outcomes.

Authors:  Ahmed F Kotb; Lysanne Campeau; Jacques Corcos
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

5.  Transplantation of mature adipocyte-derived dedifferentiated fat cells for the treatment of vesicoureteral reflux in a rat model.

Authors:  Yuichiro Ikado; Daisuke Obinata; Taro Matsumoto; Yasutaka Murata; Koichiro Kano; Noboru Fukuda; Kenya Yamaguchi; Satoru Takahashi
Journal:  Int Urol Nephrol       Date:  2016-09-28       Impact factor: 2.370

6.  Autologous fibroblast transplantation at the vesico-ureteral junction as potential reconstructive cell replacement in an animal model.

Authors:  Renate Pichler; Guenter Klima; Elisabeth Richter; Rainer Marksteiner; Viktoria Mayr; Viktor Skradski; Wolfgang Horninger; Josef Oswald
Journal:  World J Urol       Date:  2012-08-04       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.